Neurodevelopmental outcomes · preterm born neonates
Summary of findings table ‐ Early amino acids showed no clear difference in neurodevelopmental outcome assessed by any standard tool compared with late amino acids (low certainty).
1 finding from 1 review
All‐cause mortality at 28 days and before discharge from hospital · preterm born neonates
1 finding from 1 review
Nitrogen balance · preterm born neonates
1 finding from 1 review
Resolution of ear discharge ‐ measured at 1 to 2 weeks · people (of any age) with CSOM
It is very uncertain whether quinolones changes resolution of ear discharge ‐ measured at 1 to 2 weeks compared with aminoglycosides (very low certainty).
1 finding from 1 review
Resolution of ear discharge ‐ measured after 4 weeks · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain (otalgia) or discomfort or local irritation · people (of any age) with CSOM
1 finding from 1 review
Hearing · people (of any age) with CSOM
1 finding from 1 review
Serious complications · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Suspected ototoxicity · people (of any age) with CSOM
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
1 finding from 1 review
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
4 findings from 1 review
OR 1.72 [1.24, 2.4]
10 studies · 1266 participants
Low
OR 1.53 [0.93, 2.5]
6 studies · 756 participants
Low
OR 2.18 [1.25, 3.8]
3 studies · 345 participants
Low
Show 1 more finding
Progression‐free survival · people with advanced gastric cancer
Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).
1 finding from 1 review
Progression‐free survival (PSF) · people with advanced gastric cancer
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
3 findings from 1 review
HR 0.85 [0.72, 1]
5 studies · 741 participants
Moderate
HR 0.51 [0.33, 0.77]
1 study · 90 participants
Moderate
HR 0.74 [0.66, 0.84]
2 studies · 809 participants
High
Treatment‐related death · people with advanced gastric cancer
Irinotecan showed no clear difference in treatment‐related death compared with non‐irinotecan‐containing regimens (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether irinotecan changes treatment discontinuation due to toxicity compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)
Outcome not reported · People with Von Willebrand disease undergoing minor oral surgery or dental extractions
The review found no eligible studies for this question.
1 finding from 1 review